Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis [2]

New England Journal of Medicine

Volumn 367, Issue 9, 2012, Pages 870-

  Izumi, Shinyu ^a   Iikura, Motoyasu ^a   Hirano, Satoshi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; PLACEBO; PREDNISONE;

FIBROSING ALVEOLITIS; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MORTALITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; FEMALE; HUMAN; LUNG FIBROSIS; MALE; NOTE;

ACETYLCYSTEINE; AZATHIOPRINE; FEMALE; HUMANS; MALE; PREDNISONE; PULMONARY FIBROSIS;

EID: 84865482223     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1207471     Document Type: Letter

References (2)

1. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004;350:2487-98.
2. Roblot F, Godet C, Le Moal G, et al. Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients. Eur J Clin Microbiol Infect Dis 2002;21:523-31.